Keros Therapeutics urges stockholders to vote for company’s director nominees

Keros recommends stockholders vote “FOR” each of its three director nominees: Mary Ann Gray, Ph.D., Ran Nussbaum and Alpna Seth, Ph.D. The company said in part, “At the upcoming Annual Meeting, you have an important decision to make regarding your investment in Keros. Our Board of Directors is focused on acting in the best interests of the Company and its stockholders and is in the middle of a comprehensive strategic review process to evaluate all potential options to maximize stockholder value, including a sale or other business combination transaction, continued investment in the Company’s pipeline, and/or return of excess capital or any combination thereof, and expects to announce an interim update by June 9, 2025. While that process should be the Board’s top priority and focus, ADAR1 Capital Management has launched a distracting and self-serving campaign designed to dictate the outcome of the strategic review by eliminating all options for the Board except an immediate liquidation strategy.We strongly recommend that you vote “FOR” each of Keros’ three highly qualified and experienced director nominees and protect the value of your investment…Despite failing to nominate directors during the Company’s well-established nomination window, and despite significant engagement from members of the Keros Board and management team, ADAR1 has determined to advance its own self-serving agenda at the eleventh hour before our Annual Meeting, which is threatening and distracting from the Board’s top priority – successfully completing the strategic alternatives review process to maximize value for ALL stockholders. The Choice is Clear This is a critical time for Keros as it advances its pipeline and determines the right path forward. The Keros Board will continue to make decisions that are in the best interests of its stockholders to generate long-term value. We urge you to vote in favor of each of Keros’ three director nominees, Mary Ann Gray, Ph.D., Ran Nussbaum and Alpna Seth, Ph.D.”